Page last updated: 2024-12-11
tris(dibenzylideneacetone)dipalladium
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
tris(dibenzylideneacetone)dipalladium: N-myristoyltransferase-1 inhibitor that is effective against melanoma growth in vitro and in vivo [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9811564 |
MeSH ID | M0525661 |
Synonyms (80)
Synonym |
---|
AC-18117 |
tris(dibenzylideneacetone)dipalladium(0), 97% |
51364-51-3 |
tris(dibenzylideneacetone)dipalladium(0) |
T2184 |
tris(dibenzylideneacetone)dipalladium (o) |
tris(dibenzylideneacetone)dipalladium |
tris(dibenzylideneacetone)dipalladium (0) |
pd2(dba)3 |
tris(dibenzylideneacetone) dipalladium |
tris(dibezylideneacetone)dipalladium |
BP-10487 |
GC10024 |
AKOS015888228 |
tris((1e,4e)-1,5-diphenylpenta-1,4-dien-3-one) dipalladium |
mfcd00013310 |
tris(dibenzylideneaceton)dipalladium (0) |
pd2(dba) 3 |
tris-(dibenzylideneaceton)-dipalladium(0) |
tris(dibenzylidene acetone)dipalladium |
tris(dibenzylidene-acetone)dipalladium(0) |
tris(dibenzylideneacetone)-dipalladium(0) |
tris(dibenzylideneacetone)di palladium(0) |
tris(dibenzylidene acetone)dipalladium(0) |
tris(dibenzylidene acetone)di-palladium |
tris(dibenzylideneacetone)di-palladium(0) |
tris(dibenzilideneacetone)dipalladium(0) |
CYPYTURSJDMMMP-WVCUSYJESA-N |
tris(dibenzylideneacetone)di-palladium (0) |
tris(dibenzyl-ideneacetone)dipalladium(0) |
tris(dibenzylideneacetone)-dipalladium |
tris(dibenzylideneacteone)dipalladium(0) |
tris (dibenzylidene acetone)dipalladium (0) |
tris(dibenzylidene-acetone)dipalladium |
tris(dibenzylidene acetone)dipalladium (0) |
pd2 dba3 |
pd2 (dba) 3 |
tris(dibenzylideneacetone)-di-palladium (0) |
tris(dibenzylideneaceton)dipalladium |
tris(dibenzylideneacetone)-dipalladium (0) |
tris-(dibenzylideneacetone)dipalladium |
tris-(dibenzilideneacetone)dipalladium(0) |
tris-(dibenzylideneacetone)dipalladium(0) |
tris-(dibenzylideneaceton)-dipalladium |
tris(dibenzylidene acetone)-dipalladium |
tris(dibenzylidene acetone)dipalladium-(0) |
tris(dibenzyl-ideneacetone)dipalladium (0) |
tris(dibenzylideneacetone)dipaliadium(0) |
tris-(dibenzylidene-acetone)dipalladium |
tris-(dibenzylideneacetone)dipalladium (0) |
tris(dibenzilideneacetone)dipalladium |
tris (dibenzylidene acetone)dipalladium |
tris(dibenzylidene-acetone)dipalladium (0) |
tris (dibenzylideneacetone)dipalladium(0) |
tris(dibezylideneacetone) dipalladium |
tris (dibenzylideneacetone)dipalladium (0) |
tris(dibenzylideneacetone)-di-palladium |
tris-(dibenzylideneacetone)-dipalladium (0) |
tris-(dibenzylideneacetone)di-palladium(0) |
tris-(dibenzylideneacetone)di-palladium |
tris(dibenzylideneaceton)dipalladium(0) |
tris(dibenzylideneaceton)-dipalladium(0) |
tris (dibenzylideneacetone)dipalladium |
tris[dibenzylideneacetone]dipalladium (0) |
tris(dibenzylideneactone)dipalladium |
pd2 (dba)3 |
tris(dibenzyliden-eacetone)dipalladium(0) |
tris-(dibenzylideneacetone)-dipalladium |
pd2dba3 |
tris(dibenzylideneacteone)dipalladium (0) |
tris(dibenzylideneacetorie)dipalladium(0) |
tris(dibenzylideneacetone)palladium(0) |
J-525135 |
CS-W007326 |
tris[dibenzylideneacetone]dipalladium(0), chemdose(tm) tablets, loading: 0.5mumol per tablet (1mumol pd per tablet) |
GS-3242 |
tris(dibenzylideneacetone)dipalladium (pd2(dba)3) |
tris(dibenzylideneacetone)dipalladium(0) 21.5% min pd grade |
AMY11702 |
tris-dba palladium |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 7 (63.64) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |